Welcome!

News Feed Item

Milestone Scientific Announces Financial Results for the Second Quarter of 2014

Revenue Increases 10.0% to $2.5 Million; Domestic Handpiece Sales Increase 22.0%; International Handpiece Sales Increase 20.1%; Domestic Sales Increase 9.3%; International Sales Increase 10.7%; Shareholders' Equity Increases to $15.3 Million

LIVINGSTON, NJ--(Marketwired - August 14, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results and provided a business update for the three and six months ended June 30, 2014.

Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "We are making progress advancing our epidural and intra-articular instruments through the regulatory process. We have developed a broad platform of computer-controlled injection technologies serving a wide array of medical applications and we look forward to announcing additional medical instruments later this year."

"We are also adding strategic resources that we believe will help us advance both our dental and medical instruments. We recently announced the appointment of Gian Domenico Trombetta as Chief Executive Officer of the dental division. He has an impressive track record leading high growth companies across a broad range of industries. We also announced the appointment as Marketing Consultant of Steven Robins, who has overseen the marketing and operations for billion dollar divisions of Fortune 500 healthcare and consumer product companies. Both executives bring valuable industry contracts and expertise."

Mr. Osser continued, "Total revenue for the second quarter of 2014 increased 10.0% to $2.5 million. We achieved a 22.0% increase in domestic handpiece sales and a 20.1% increase in international handpiece sales. This growth in domestic handpieces is due in part to the greater transparency we have with our customers, through our exclusive distributor Aseptico. We are able to establish direct relationships with the dentists and train them properly so they can utilize a greater number of handpieces per year."

"During the second quarter, we announced a $10 million financing which enables us to accelerate the development of additional medical instruments based on our patented CompuFlo and Dynamic Pressure Sensing technologies. Future medical applications of our technologies which will benefit from this investment could include colorectal surgery, podiatry, dermatology, orthopedics, nasal and sinus surgery, and cosmetic surgery, among others. The financing also allows us to more aggressively market and sell our dental instruments and handpieces in the United States and worldwide. As a result of this financing, we now have over $15 million of shareholders' equity. Given the strength of our balance sheet and continued positive cash flow from operations, we believe we are well positioned in the months and years ahead."

Revenue for the three months ended June 30, 2014 was $2.5 million versus $2.3 million for the second quarter of 2013. Domestic instrument sales decreased by $33,376 or 8.7% in the second quarter of 2014 versus the same period in 2013 due to lower distributor purchase prices for the STA instruments for a limited time period. The strategy is to facilitate the deployment of the STA instruments at a faster pace, thus generating recurring handpiece revenue. Domestic handpiece sales increased by $146,527, or 22.0% in 2014 over 2013. On the international front, instrument sales decreased by $34,677 or 9.4% in the second quarter of 2014 versus the same period in 2013. International handpiece sales increased by $162,758 or 20.1% in the second quarter of 2014 versus 2013. Gross profit for the second quarter of 2014 was $1.6 million or 63.6% of revenue versus $1.5 million or 67.3% of revenue for the second quarter of 2013. The decrease in gross margin reflected the lower pricing strategy on the instruments to drive handpiece sales. Operating income for the second quarter of 2014 was $47,507 versus an income of $151,113 for the second quarter of 2013. Net loss for the second quarter of 2014 was ($169,457), or $(0.01) per share, versus an income of $74,009 or $0.00 per share for the comparable period in 2013. Net loss for the second quarter of 2014 includes a Loss on Earnings from Medical Joint Venture of ($213,193) compared to ($47,093) for the three months ended June 30, 2013. Also, the June 30, 2013 net income included the positive impact of the reversal of the bad debt reserve for uncollectable accounts in 2013 that did not occur in 2014.

Revenue for the six months ended June 30, 2014 was $5.1 million versus $4.8 million for the six months ended June 30, 2013. In the domestic market, total revenue was approximately equal in both periods. On the international front, total revenue increased by $345,924 to $2.7 million versus $2.4 million for the same period in 2013. Gross profit for the six months ended June 30, 2014 was $3.3 million or 65.0% of revenue versus $3.2 million or 67.4% of revenue for the six months ended June 30, 2013. Operating income for the six months ended June 30, 2014 was $376,753 versus an income of $318,874 for the six months ended June 30, 2013. Net income for the six months ended June 30, 2014 was $25,377, or $0.00 per share, versus an income of $224,754, or $0.01 per share, for the comparable period in 2013. Net income for the six months ended June 30, 2014 includes a Loss on Earnings from Medical Joint Venture of ($343,716) compared to ($47,093) for the same period last year.

Milestone's executive management team will host a teleconference on Thursday, August 14, 2014 at 8:30 A.M. Eastern Time to discuss the company's financial results. 

The conference call will be available via telephone by dialing toll free 1-888-359-3627 and entering the pass code 8220117 or on the company's website at www.milestonescientific.com. For those unable to participate at that time, a replay of the call will be archived on the company's website or can be accessed by dialing 1-888-203-1112 and entering the pass code 8220117. The replay will be available for 90 days.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(tables follow)

                                                                            
                         MILESTONE SCIENTIFIC INC.                          
                     CONDENSED STATEMENTS OF OPERATIONS                     
                                (Unaudited)                                 
                                                                            
                          Three Months Ended June    Six Months Ended June  
                                    30,                       30,           
                         ------------------------  ------------------------ 
                             2014         2013         2014         2013    
                         -----------  -----------  -----------  ----------- 
                                                                            
Product sales            $ 2,506,932  $ 2,278,235  $ 5,127,766  $ 4,767,778 
Cost of products sold        912,406      744,108    1,795,403    1,556,152 
                         -----------  -----------  -----------  ----------- 
  Gross profit             1,594,526    1,534,127    3,332,363    3,211,626 
                         -----------  -----------  -----------  ----------- 
                                                                            
Selling, general and                                                        
 administrative expenses   1,517,854    1,340,129    2,910,724    2,728,031 
Research and development                                                    
 expenses                     29,165       42,885       44,885      164,722 
                         -----------  -----------  -----------  ----------- 
Total operating expenses   1,547,019    1,383,014    2,955,609    2,892,752 
                         -----------  -----------  -----------  ----------- 
Income from operations        47,507      151,113      376,754      318,874 
Other income (expenses)                                                     
  Other income                     -            -            -       17,543 
  Interest income                                                           
   (expense)                     635      (30,011)         161      (64,569)
  Loss from Medical                                                         
   Joint Venture            (213,193)     (47,093)    (343,716)     (47,093)
  Loss from Education                                                       
   Joint Venture              (4,406)           -       (7,822)           - 
                         -----------  -----------  -----------  ----------- 
    Total other                                                             
     expenses, net          (216,964)     (77,104)    (351,377)     (94,119)
                         -----------  -----------  ===========  =========== 
Net (loss) income                                                           
 applicable to common                                                       
 stockholders            $  (169,457) $    74,009  $    25,377  $   224,754 
                         ===========  ===========  ===========  =========== 
                                                                            
Net (loss) income per                                                       
 share applicable to                                                        
 common stockholders -                                                      
  Basic                  $     (0.01) $      0.00  $      0.00  $      0.01 
                         ===========  ===========  ===========  =========== 
  Diluted                $     (0.01) $      0.00  $      0.00  $      0.01 
                         ===========  ===========  ===========  =========== 
Weighted average shares                                                     
 outstanding and to be                                                      
 issued -                                                                   
  Basic                   20,246,281   16,744,951   19,196,919   16,765,602 
                         ===========  ===========  ===========  =========== 
  Diluted                 20,246,281   17,056,219   22,206,942   17,124,936 
                         ===========  ===========  ===========  =========== 
                                                                            
                                                                            
                          MILESTONE SCIENTIFIC INC.                         
                          CONDENSED BALANCE SHEETS                          
                                                                            
                                                   June 30,    December 31, 
                                                     2014          2013     
                                                  (Unaudited)               
                                                 ------------  ------------ 
                     ASSETS                                                 
Current Assets:                                                             
  Cash and cash equivalents                      $  1,121,721  $  1,147,198 
  Treasury Bills                                    9,498,498             - 
  Accounts receivable, net of allowance for                                 
   doubtful accounts of $5,000 as of June 30,                               
   2014 and $5,000 as of December 31, 2013          1,443,386     1,532,856 
  Inventories                                       1,964,390     1,321,652 
  Advances on contracts                             1,454,807       727,478 
  Prepaid expenses and other current assets           161,560       150,451 
                                                 ------------  ------------ 
    Total current assets                           15,644,362     4,879,635 
Advances on contracts                                 218,875     1,580,874 
Investment in Milestone Medical Inc                   760,750       924,115 
Investment in Milestone Education LLC                  34,261        42,082 
Furniture, Fixtures & Equipment net of                                      
 accumulated depreciation of $454,818 as of June                            
 30, 2014 and $476,884 as of December 31, 2013         38,153        23,988 
Patents, net of accumulated amortization of                                 
 $537,687 as of June 30, 2014 and $498,502 as of                            
 December 31, 2013                                    552,550       591,735 
Other assets                                           12,917        12,917 
                                                 ------------  ------------ 
      Total assets                               $ 17,261,868  $  8,055,346 
                                                 ============  ============ 
                                                                            
      LIABILITIES AND STOCKHOLDERS' EQUITY                                  
Current Liabilities:                                                        
  Accounts payable                               $    983,972  $  2,020,368 
  Customer advances                                   209,000             - 
  Accrued expenses and other payables                 754,538       515,133 
                                                 ------------  ------------ 
    Total current liabilities                       1,947,510     2,535,501 
                                                 ------------  ------------ 
                                                                            
Commitments and Contingencies                                               
                                                                            
Stockholders' Equity                                                        
  Series A Convertible Preferred Stock, par                                 
   value $.001, authorized 5,000,000 shares,                                
   7,000 and zero shares issued and outstanding,                            
   respectively                                  $          7  $          - 
  Common stock, par value $.001; authorized                                 
   50,000,000 shares; 21,074,786 shares issued                              
   875,322 shares to be issued and 21,041,453                               
   shares outstanding as of June 30, 2014;                                  
   17,759,540 shares issued, 1,839,930 shares to                            
   be issued, and 17,726,207 shares outstanding                             
   as of December 31, 2013                             21,949        19,599 
  Additional paid-in capital                       76,443,979    66,677,200 
  Accumulated deficit                             (60,240,061)  (60,265,438)
  Treasury stock, at cost, 33,333 shares             (911,516)     (911,516)
                                                 ------------  ------------ 
    Total stockholders' equity                     15,314,358     5,519,845 
                                                 ------------  ------------ 
      Total liabilities and stockholders' equity $ 17,261,868  $  8,055,346 
                                                 ============  ============ 
                                                                            

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Secure Channels, a cybersecurity firm, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Secure Channels, Inc. offers several products and solutions to its many clients, helping them protect critical data from being compromised and access to computer networks from the unauthorized. The company develops comprehensive data encryption security strategie...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
Vulnerability management is vital for large companies that need to secure containers across thousands of hosts, but many struggle to understand how exposed they are when they discover a new high security vulnerability. In his session at 21st Cloud Expo, John Morello, CTO of Twistlock, will address this pressing concern by introducing the concept of the “Vulnerability Risk Tree API,” which brings all the data together in a simple REST endpoint, allowing companies to easily grasp the severity of t...
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
Cloud adoption is often driven by a desire to increase efficiency, boost agility and save money. All too often, however, the reality involves unpredictable cost spikes and lack of oversight due to resource limitations. In his session at 20th Cloud Expo, Joe Kinsella, CTO and Founder of CloudHealth Technologies, tackled the question: “How do you build a fully optimized cloud?” He will examine: Why TCO is critical to achieving cloud success – and why attendees should be thinking holistically ab...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyer belt between the Software Factory and production stages. Artifacts are m...
Connecting to major cloud service providers is becoming central to doing business. But your cloud provider’s performance is only as good as your connectivity solution. Massive Networks will place you in the driver's seat by exposing how you can extend your LAN from any location to include any cloud platform through an advanced high-performance connection that is secure and dedicated to your business-critical data. In his session at 21st Cloud Expo, Paul Mako, CEO & CIO of Massive Networks, wil...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, presented an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He then expounded on the industry issues he frequently came up against as an analyst, and ...
Cloud resources, although available in abundance, are inherently volatile. For transactional computing, like ERP and most enterprise software, this is a challenge as transactional integrity and data fidelity is paramount – making it a challenge to create cloud native applications while relying on RDBMS. In his session at 21st Cloud Expo, Claus Jepsen, Chief Architect and Head of Innovation Labs at Unit4, will explore that in order to create distributed and scalable solutions ensuring high availa...
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...